The novel IL-6R antibody HZ0412a and Tocilizumab, the latter being already approved by FDA and used in patients with, for example, rheumatoid arthritis, display an KD of 14.5 nM and 38.8 nM respectively (46). The gene discussed is IL6R; the disease is rheumatoid arthritis.